

Clinical Policy: Plozasiran (Redemplo)

Reference Number: CP.PHAR.721

Effective Date: 11.18.25

Last Review Date: 08.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Plozasiran (Redemplo[®]) is an apolipoprotein C-III (*apoC-III*)-directed small interfering ribonucleic acid (siRNA).

FDA Approved Indication(s)

Redemplo is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Redemplo is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Familial Chylomicronemia Syndrome (must meet all):**

1. Diagnosis of FCS as evidenced by both of the following (a and b):
 - a. Fasting triglycerides ≥ 1000 mg/dL or ≥ 11.2 mmol/L (lab must be dated within 90 days);
 - b. One of the following (i or ii, *see Appendix D*):
 - i. Genetic testing confirms the presence a loss-of-function mutation in an FCS-causing gene (e.g., LPL, APOC2, APOA5, GPIHBP1, LMF1);
 - ii. Genetic test results are inconclusive and North American familial chylomicronemia syndrome (NAFCS) score > 45 ;
2. Prescribed by or in consultation with an endocrinologist, lipid specialist, cardiologist, gastroenterologist, or pancreatologist;
3. Age ≥ 18 years;
4. Failure of a ≥ 3 consecutive month trial of one of the following (a or b) in the last 6 months at up to maximally indicated doses, unless clinically significant adverse effects are experienced or both are contraindicated;*

**For Illinois HIM requests, the step therapy requirements above do not apply per IL HB 5395*

 - a. Fibrate therapy (e.g. fenofibrate, gemfibrozil);
 - b. Omega-3 fatty acids (omega-3-acid ethyl esters [Lovaza[®]], icosapent ethyl [Vascepa[®]]);
5. Redemplo is not prescribed concurrently with Tryngolza[®];
6. Dose does not exceed 25 mg every 3 months.

Approval duration:

Medicaid/HIM/ICHRA – 6 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Familial Chylomicronemia Syndrome (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by reduction in fasting triglycerides from baseline;
3. Member is concurrently receiving standard of care TG-lowering treatment (e.g., fibrates or omega-3 fatty acids), if clinically appropriate;
4. Redemplo is not prescribed concurrently with Tryngolza;
5. If request is for a dose increase, new dose does not exceed 25 mg every 3 months.

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of

- business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
 2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

APOC2: apolipoprotein C-II

APOC3: apolipoprotein C-III

APOA5: apolipoprotein C-VI

FCS: familial chylomicronemia syndrome

FDA: Food and Drug Administration

GPIHBP1: glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1

LMF1: lipase maturation factor 1

LPL: lipoprotein lipase

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Fibrates		
fenofibrate (TriCor [®])	Refer to prescribing information	Refer to prescribing information
gemfibrozil (Lopid [®])	600 mg PO BID	1,200 mg/day
Omega-3 fatty acids		
icosapent ethyl (Vascepa [®])	2 g PO BID	4 g/day
omega-3-acid ethyl esters (Lovaza [®])	4 g PO QD or 2 g PO BID	4 g/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- FCS may also be referred to as lipoprotein lipase deficiency (LPLD), type 1 hyperlipoproteinemia, endogenous hypertriglyceridemia, familial fat-induced hypertriglyceridemia, familial hyperchylomicronemia, familial LPL deficiency, hyperlipidemia Type I (Fredrickson), hyperlipoproteinemia type IA, lipase D deficiency, chylomicronemia syndrome, familial chylomicronemia, hyperchylomicronemia familial, hyperlipemia idiopathic Burger-Grutz type, lipase D deficiency, or Burger-Grutz syndrome.
- FCS is caused by biallelic loss-of-function homozygous, compound heterozygous, or double heterozygous pathogenic variants in LPL, APOC2, APOA5, GPIHBP1, and/or LMF1.
- A specific diagnosis of FCS can be made based on clinical characteristics. Genetic testing can be used for additional information; however, a negative genetic test does not necessarily exclude a diagnosis of FCS because not all mutations are known. If genetic testing is inconclusive, the NAFCS score is an appropriate and reliable tool to support the diagnosis of FCS.

Appendix E: North American Familial Chylomicronemia Syndrome (NAFCS) Score

- NAFCS Score: clinical tool used to distinguish FCS from multifactorial chylomicronemia syndrome (MCS) in patients with severe hypertriglyceridemia.

Apolipoprotein (ApoB) in patients with severe hypertriglyceridemia.		
NAFCS Criteria	Points	Member's Score
Current age		
< 1 years old	0	Place highest score here (0, 12)
≥ 1 – 9 years old	12	
≥ 10 years old	0	
If age ≥ 10 years, hypertriglyceridemia (HTG) onset		
≥ 10 years old	0	Place highest score here (0, 12)
< 10 years old	12	
Body mass index (BMI)		
≥ 25mg/m ² or ≥ 85 th percentile	0	Place highest score here (0, 9)
< 25 kg/m ² or < 85 th percentile	9	
History of pancreatitis		
Neither abdominal pain nor pancreatitis	0	Place highest score here (0, 9, 16)
Abdominal pain but no pancreatitis	9	
Pancreatitis	16	
Presence of secondary factors that may contribute to HTG		
≥ 1	0	Place highest score here (0, 11)
None	11	
All triglycerides (TG) > 880 mg/dL		
No	0	Place highest score here (0, 13)
Yes	13	
Ratio TG/TC > 8 (when measured in mg/dL)		
No	0	Place highest score here (0, 8)
Yes	8	

NAFCS Criteria	Points	Member's Score
Apo B < 1 g/L		
No	0	Place highest score here (0, 12)
Yes	12	
Additional points		
If patients is ≥ 1 - 9 years old AND has no secondary factors	7	
If ratio TG/TC > 8 AND apo B < 1 g/dL	7	
If ratio TG/TC > 8 AND has no secondary factors	5	
TOTAL SCORE	Unlikely: < 30 Possible: 30 – 44 Likely: 45 – 59 Definite: > 60	Place score total here

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
FCS	25 mg SC every 3 months	25 mg/3 months

VI. Product Availability

Pre-filled syringe: 25 mg/0.5 mL

VII. References

1. Redempho Prescribing Information. Pasadena, CA: Arrowhead Pharmaceuticals, Inc.; November 2025. Available at: <https://redempho.com>. Accessed February 10, 2026.
2. Watts GF, Rosenson RS, Hegele RA, et al; PALISADE Study Group. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. *N Engl J Med*. 2025 Jan 9;392(2):127-137. doi: 10.1056/NEJMoa2409368.
3. Moulin P, Dufour R, Aversa M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". *Atherosclerosis*. 2018 Aug;275:265-272. doi: 10.1016/j.atherosclerosis.2018.06.814.
4. Javed F, Hegele RA, Garg A, et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol*. 2025 May-Jun;19(3):382-403. doi: 10.1016/j.jacl.2025.03.013
5. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 Executive Summary. *Endocr Pract*. 2020 Oct;26(10):1196-1224. doi: 10.4158/CS-2020-0490.
6. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. *J Am Coll Cardiol*. 2026 Mar 13:S0735-1097(25)10254-4. doi: 10.1016/j.jacc.2025.11.016

7. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol*. 2025 Jan-Feb;19(1):83-94. doi: 10.1016/j.jacl.2024.09.008.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
C9399	Unclassified drugs or biologicals
J3490	Unclassified drugs

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	02.11.25	05.25
Drug is now FDA approved – criteria updated per FDA labeling; consolidated FCS diagnostic criteria; added requirement for “history of elevated triglycerides in excess of 1,000 mg/dL at least three times” for clinically suggestive FCS per clinical trial design; removed failure of fibrates and omega-3 fatty acids; references reviewed and updated.	12.12.25	02.26
2Q 2026 annual review: added option to be prescribed by gastroenterologist or pancreatologist; in continued therapy, added Redemplo is not prescribed concurrently with Tryngolza; references reviewed and updated. Added ICHRA line of business.	04.08.26	05.26
Per 2026 guideline updates: revised fasting triglyceride requirement to ≥ 1000 mg/dL; revised clinically suggestive FCS requirement to inconclusive genetic test results and NAFCS score > 45 ; added trial and failure of fibrate therapy or omega-3 fatty acids. Added continued therapy requirement for concurrent use of standard of care TG-lowering treatment if clinically appropriate.	07.14.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2025 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise

published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.